The DSMB is an independent panel of experts established by NIAID and charged with the responsibility of monitoring the progress of trials, the safety of participants, and the efficacy of treatments being tested. The DSMB also makes recommendations to NIAID concerning continuation, termination or modification of the studies based on observed beneficial or adverse effects of any of the interventions under study. This panel is funded separately by NIAID.
Researchers- ideally independent of the trials they monitor- who periodically review data from blinded, placebo-controlled trials. A DSMB can stop a trial if toxicities are found or if treatment is proved beneficial. See also independent data-monitoring committee.
A group of independent experts that review the research data periodically to ensure the safety of the participants